home / stock / fblg / fblg news

FBLG News and Press, FibroBiologics Inc. From 06/16/25

Stock Information
Company Name: FibroBiologics Inc.
Stock Symbol: FBLG
Market: NASDAQ
Website: fibrobiologics.com
Menu
FBLG FBLG Quote FBLG Short FBLG News FBLG Articles FBLG Message Board
Get FBLG Alerts

News, Short Squeeze, Breakout and More Instantly...
FBLG - FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...
FBLG - FibroBiologics to Present at the BIO International Convention 2025

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...

FBLG - FibroBiologics announces CFO appointment

2025-06-09 08:42:25 ET Read the full article on Seeking Alpha For further details see: FibroBiologics announces CFO appointment

FBLG - FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...
FBLG - FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts an...

FBLG - FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast...

FBLG - Expected US Company Earnings on Tuesday, May 13th, 2025

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...
FBLG - FBLG - Historical Price Movements Surrounding Earnings

2025-05-12 18:48:12 ET FibroBiologics, Inc. Common Stock (FBLG) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 7.46%. The average open to low on the day of earnings was -6.25%. The aver...

FBLG - FBLG - Historical Earnings Price Analysis

2025-05-12 18:43:11 ET FibroBiologics, Inc. Common Stock (FBLG) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in FBLG stock price following earnings has averaged ±0.86% , with a median ...

FBLG - FibroBiologics Presenting at the ThymUS 2025 Meeting

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts ...
Previous 10 Next 10